Quantcast
Home > Quotes > ORMP
ORMP

Oramed Pharmaceuticals Inc. Common Stock (ORMP) Quote & Summary Data

$4.74
*  
0.02
0.42%
Get ORMP Alerts
*Delayed - data as of Aug. 17, 2018 14:52 ET  -  Find a broker to begin trading ORMP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ORMP Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.68 / $ 4.73
1 Year Target
25
Today's High / Low
$ 4.81 / $ 4.68
Share Volume
8,166
50 Day Avg. Daily Volume
48,164
Previous Close
$ 4.76
52 Week High / Low
$ 11.34 / $ 4.66
Market Cap
82,298,795
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.39

Intraday Chart

Shares Traded

Share Volume:
8,166
50 Day Avg. Daily Volume:
48,164

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.88

Trading Range

The current last sale of $4.74 is 1.72% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.81 $ 11.34
 Low: $ 4.68 $ 4.66

Company Description (as filed with the SEC)

We are a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Oral insulin: We are seeking to revolutionize the treatment of diabetes through our proprietary flagship product, an orally ingestible insulin capsule, or ORMD-0801. In August 2017, we had a call with the U.S. Food and Drug Administration, or FDA, regarding ORMD-0801. During the call, the FDA advised that the regulatory pathway for the submission of ORMD-0801 would be a Biologics License Application, or BLA. Such a pathway would grant us 12 years of marketing exclusivity for ORMD-0801, if approved, and an additional six months of exclusivity may be granted to us if the product also receives approval for use in pediatric patients.  ... More ...  


Risk Grade

Where does ORMP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.74
Open Date:
Aug. 17, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info